Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes

INTRODUCTION: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. AIMS: To update the evidence and provide an overview of the available data on ticagrelor. EVIDENCE REVIEW: Peer reviewed articles published a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombo, Bernardo, Díez, José G
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065559/
https://www.ncbi.nlm.nih.gov/pubmed/21468241
http://dx.doi.org/10.2147/CE.S9510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065559/
https://www.ncbi.nlm.nih.gov/pubmed/21468241
http://dx.doi.org/10.2147/CE.S9510

Ejemplares similares